Prosecution Insights
Last updated: April 19, 2026
Application No. 14/443,862

SENSORILY ATTRACTIVE HYDRODISPERSION COMPRISING WAXES

Non-Final OA §103
Filed
May 19, 2015
Examiner
ELENISTE, PIERRE PAUL
Art Unit
1622
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
BEIERSDORF AG
OA Round
8 (Non-Final)
39%
Grant Probability
At Risk
8-9
OA Rounds
3y 6m
To Grant
71%
With Interview

Examiner Intelligence

Grants only 39% of cases
39%
Career Allow Rate
27 granted / 69 resolved
-20.9% vs TC avg
Strong +32% interview lift
Without
With
+31.6%
Interview Lift
resolved cases with interview
Typical timeline
3y 6m
Avg Prosecution
53 currently pending
Career history
122
Total Applications
across all art units

Statute-Specific Performance

§101
2.1%
-37.9% vs TC avg
§103
48.9%
+8.9% vs TC avg
§102
16.5%
-23.5% vs TC avg
§112
20.8%
-19.2% vs TC avg
Black line = Tech Center average estimate • Based on career data from 69 resolved cases

Office Action

§103
DETAILED ACTION The present application is being examined under the pre-AIA first to invent provisions. RCE: A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 08/29/2025 has been entered. Status of the claims: Newly presented claims 59-75, 77, and 79-80 are pending. Priority: This application is a 371 of PCT/EP2013/073586 (11/12/2013) and claims foreign priority to GERMANY 10 2012 221 227.2 (11/20/12). Claim Construction Exemplary independent claims 59 and 70 are to “A hydrodispersion …” which “comprises” the ingredients listed in the claim and does not exclude additional, unrecited elements. See, e.g., Mars Inc. v. H.J. Heinz Co., 377 F.3d 1369, 1376, 71 USPQ2d 1837, 1843 (Fed. Cir. 2004) (“[L]ike the term ‘comprising,’ the terms ‘containing’ and ‘mixture’ are open-ended.”); Invitrogen Corp. v. Biocrest Manufacturing, L.P., 327 F.3d 1364, 1368, 66 USPQ2d 1631, 1634 (Fed. Cir. 2003) (“The transition ‘comprising’ in a method claim indicates that the claim is open-ended and allows for additional steps.”); Genentech, Inc. v. Chiron Corp., 112 F.3d 495, 501, 42 USPQ2d 1608, 1613 (Fed. Cir. 1997) (“Comprising” is a term of art used in claim language which means that the named elements are essential, but other elements may be added and still form a construct within the scope of the claim.); Moleculon Research Corp. v. CBS, Inc.,793 F.2d 1261, 229 USPQ 805 (Fed. Cir. 1986); In re Baxter, 656 F.2d 679, 686, 210 USPQ 795, 803 (CCPA 1981); Ex parte Davis, 80 USPQ 448, 450 (Bd. App. 1948) (“comprising” leaves “the claim open for the inclusion of unspecified ingredients even in major amounts”). See also MPEP 2111.03. The claim term “hydrodispersion” is defined in the specification as a “low-emulsifier or emulsifier-free formulations” that contain “small amounts of emulsifier (up to 2% by weight)” (Specification at page 1, lines 12-20). Hydrodispersions are also defined as a dispersion of liquid, either semisolid or solid inner lipid phase in an outer aqueous phase (Id.). Therefore, the claim term “hydrodispersion” is interpreted as a composition dispersed in an outer aqueous phase and having small amounts of emulsifier. Claims 75-78 are to cosmetic or dermatological compositions used for skincare or eye cream. Recitations of an intended utility in the preamble of the product claim which otherwise stand alone is not considered a further limitation of the claim. A preamble is generally not accorded any patentable weight where it merely recites the purpose of a process or the intended use of a structure, and where the body of the claim does not depend on the preamble for completeness but, instead, the process steps or structural limitations are able to stand alone. See In re Hirao, 535 F.2d 67, 190 USPQ 15 (CCPA 1976) and Kropa v. Robie, 187 F.2d 150, 152, 88 USPQ 478, 481 (CCPA 1951); In re Spada, 15 USPQ.2d 1655 (Fed. Cir. 1990). Such intended uses should be properly claimed as a process or method claim. See 35 U.S.C. 100(b), 101. See also, Clinical Products v. Brenner, 255 F. Supp. 131, 149 USPQ 475, 477 (DDC 1966). New Grounds of Rejection due to the Applicant’s Claim Amendments and New Claims Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102 of this title, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries set forth in Graham v. John Deere Co., 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. Claims 59-61, 63-65, 67, 68, 70, 72-75, and 79-80 are rejected under 35 U.S.C. 103 as being unpatentable over Kruse et al. (EP 1 889 596) in view of Amela et al., WO 2009/043533. Regarding claim 59, Kruse teaches A hydrodispersion (claim 1: “Cosmetic preparation of the oil-in-water type”), wherein the hydrodispersion exhibits at least one melting range between 5 C and 30 C by DSC and comprises, based on a total mass of the dispersion: (a) from 60 % to 95 % by weight of water (claim 1: “Cosmetic preparation of the oil-in-water type”; Table water “ad 100”), (b) from 0.05 % to 5 % by weight of at least one thickener (The aqueous phase may contain thickeners (Xanthan Gum) [0060], See also Examples 1-3 at pages 8-9; and comprises 0.5 or 0.3 wt.% of the thickener xanthan gum, See Examples 1-3), (c) from 2 % to 20 % by weight of one or more waxes, at least one wax having a melting point Tonset below 30°C and being selected from one or more of fats (triglycerides), mono- and diglycerides, natural and synthetic waxes, fatty alcohols, wax alcohols, fatty acids, esters of fatty alcohols and fatty acids, fatty acid amides, ([0022]: “Preferred waxes according to the invention having melting points of from 25 to 45 ° C. are those having the INCI names” hydrogenated coco-glycerides and shea butter; [0023]: “the concentration of these waxes - based on the total weight of the preparation - from the range of 1 to 10 wt.%, preferably from 2.5 to 7.5 wt.%”; Examples 1-5; Claim 7: “the wax or waxes with a melting point of 25 to 45 ° C from the group Hydrogenated Cocoglycerides, Mristyl Myristate, Myristyl Lactate, Caprylic / Capric / Isostearic / Adipic Triglyceride, Shea Butter, Stearyl Dimethicone , Hydrogenated Vegetable Oil can be chosen.”; [0022]: “Particular preference is Shea Butter, Myristyl Lactate.”), and (d) from 1 % to 10 % by weight of one or more oils ([0019]: “the concentration of light oils - based on the total weight of the preparation - from the range of 5 to 15 wt.%, preferably from 10 to 12 wt.%”), a total concentration of the one or more waxes being higher than a total concentration of the one or more oils (claim 1, [0008]: “wherein the total amount of light oils is less than the total amount of medium heavy oils and waxes”) ; (d) comprising at least one oil selected from esters of saturated and/or unsaturated, branched and/or unbranched alkane-carboxylic acids having a chain length of from 3 to 30 C atoms and saturated and/or unsaturated, branched and/or unbranched alcohols having a chain length of from 3 to 30 C atoms, esters of aromatic carboxylic acids and saturated and/or unsaturated, branched and/or unbranched alcohols having a chain length of from 3 to 30 C atoms, dialkyl ethers, dialkyl carbonates, petrolatum, paraffin oil, mineral oil, squalane, squalene, hydrogenated polyisobutene, isohexadecane, natural oils, vegetable oils, silicone oils ([0018]: Light oils - “Particularly preferred are cyclomethicones, isohexadecanes, dicaprylyl carbonates, dicapyrlyl ethers”; Examples 1-5; claim 5, [0020]: medium oils are preferably mineral oil). Kruse teaches the concentration of wax as being in the range of 1 to 10 wt.%. Kruse ([0023]; claim 8). The concentration of light oil is disclosed as being in the range of 5 to 15 wt. % ([0019]). The concentration of medium oil is disclosed as being in the range of 2.5 to 20 wt. % ([0021]). If the highest concentration of wax is picked and the lowest concentrations of the oils are picked the wax would be 10% wt.% and the oils would be 7.5 wt.% (5 wt. % light oil and 2.5 wt.% medium oil). All these ranges are disclosed by Kruse, making it obvious to pick any point in the range to make a composition according to Kruse. There is reason to pick the lowest amount of light oils because Kruse discloses that when "the total amount of light oils is less than the total amount of medium-heavy oils and waxes, can solve these tasks," i.e., of a cosmetic preparation "which can in particular improve the skin's moisture and very easy to spread on the skin, quickly absorbed and thereby should be rich and nourishing." ([0007], [0008]). With respect to the claimed "melting range between 5° C and 30° C by DSC" and melting point T onset of wax below 30° C, Kruse discloses waxes having a melting point of 25 to 45°C. [0007], [0008], [0022]). Absent evidence to the contrary, Kruse's disclosed range overlaps with the claimed range, making the claimed range prima facie obvious. See In re Peterson, 315 F.3d 1325, 1329-1330 (Fed. Cir. 2003) (when there is a range disclosed in the prior art, and the claimed range overlaps or falls within that range, there is a presumption of prima facie case obviousness (citing Titanium Metals Corp. v. Banner, 778 F.2d 775, 783 (Fed. Cir. 1985).). No evidence of criticality of the claimed ranges or unexpected results are of record. In re Geisler, 116 F.3d 1465, 1469-1470 (Fed. Cir. 1997). With respect to the selection of was, Kruse discloses shea butter is preferred ([0022]). With respect to the amount of water, Kruse discloses “ad 100” (claim 1) which is the remaining weight percent and would be within the instant claim range. With respect to the oil, Kruse discloses cyclomethicone (a silicone oil) is preferred ([0018]). One of ordinary skill in the art would have considered the same wax, amount of water, and oil as these are disclosed by Kruse. With respect to a cooling effect, Kruse ([0012]) teaches a hydrodispersion preparation that increases the skin moisture and the depth of moisture in the skin, and that the moisturizing effect persists for several hours or even for an entire day. Kruse ([0061]) teaches a list of water-based moisturizers, for example, glycerin, lactic acid and/or lactates. While Kruse does not explicitly disclose the exact phrase “cooling effect, it would have been obvious to a person of ordinary skill in the art (POSITA) to recognize and understand that hydration at the skin surface would produce a corresponding cooling sensation, due to the moisturizers. As evidence by Purnamawati (page 76, left col.) teaches “Water-based moisturizers provides cooling effect from water evaporation on the skin surface…” Therefore, a POSITA would expect hydrodispersion comprising water and humectants, would eventually produce a temporary cooling sensation by increasing the skin hydration. (Purnamawati S, Indrastuti N, Danarti R, Saefudin T. Clin Med Res. 2017 Dec;15(3-4):75-87). Furthermore, one of ordinary skill in the art routinely optimizes ratios of oils and waxes in cosmetics to improve properties such as was done by Kruse – i.e. [0040]: “improve the sensory and cosmetic properties of the formulations and, for example, cause or enhance a velvety or silky feel on the skin”. In addition, Kruse teaches [0010]: “high proportions of highly viscous, fatty and only slightly spreading oils and waxes with a melting point of 25 to 45 °C would nevertheless be light on the skin and significantly reduced stickiness and in particular can be spread very easily on the skin, be absorbed quickly and still be very rich and caring.” Thus, one of skill in the art following the teaching of Kruse would have a reasonable expectation of success in arriving at the claimed invention. Thus, claim 59 is rejected as prima facie obvious. Regarding claim 60 and 72, Kruse does not explicitly teach olus oil. However, Amela (page 2; page 20, Example 1 to 12) teaches meta-stable o/w emulsions (hydrodispersion), wherein phase C includes Cegesoft® PS 6 (olus oil) at 3% w/w, a well-known cosmetic triglyceride emollient derived from vegetable oil, reading on the instant claim. Therefore, it would have been obvious to a POSITA to modify Kruse’s teachings in view of Amela’s disclosure, by substituting hydrogenated vegetable oil with olus oil, because olus oil is a lighter triglyceride-based vegetable emollient known to offer a smoother, more aesthetically pleasant skin feel compared with a waxy hydrogenated vegetable oil, to arrive at the claimed invention. Regarding claim 61, Kruse teaches mineral oil is a preferred oil and at the low end range is 2.5% which one of ordinary skill in the art would have considered through routine optimization. Regarding claim 63, Kruse further teaches that “(b)” is xanthan gum (The aqueous phase may contain thickeners (Xanthan Gum) [0060], See also Examples 1-3 at pages 8-9; and comprises 0.5 or 0.3 wt.% of the thickener xanthan gum, See Examples 1-3). Regarding claim 64, wherein (b) comprises sodium polyacrylate, Kruse teaches thickeners “particularly advantageous from the group of polyacrylates” and carbopols ([0060]) which include sodium polyacrylate. One of ordinary skill in the art routinely interchanges elements of a formulation among those well-known in the art to optimize desirable characteristics such as what a thickener provides. Thus, one of ordinary skill in the art would reasonably consider sodium polyacrylate and arrive at the claimed invention. Regarding claim 65, Kruse teaches the wax is “hydrogenated vegetable oil” (claim 7). Regarding claim 67, Kruse teaches preferred cyclic and linear silicone oils ([0018]: cyclomethicone; [0020]: dimethicone). Regarding claim 68, Kruse teaches ad 100 water which meets the claim limitation. Regarding independent claim 70, as with the claims rejected above, Kruse teaches the hydrodispersion including water, thickener (xanthan gum), waxes (hydrogenated vegetable oil), and oils (mineral and silicone oils). Regarding claim 73, Kruse teaches preferred cyclic and linear silicone oils ([0018]: cyclomethicone; [0020]: dimethicone). Regarding claim 74, wherein (b) comprises sodium polyacrylate, Kruse teaches thickeners “particularly advantageous from the group of polyacrylates” and carbopols ([0060]) which include sodium polyacrylate. One of ordinary skill in the art routinely interchanges elements of a formulation among those well-known in the art to optimize desirable characteristics such as what a thickener provides. Thus, one of ordinary skill in the art would reasonably consider sodium polyacrylate and arrive at the claimed invention. Regarding claims 75, Kruse is entitled “cosmetic preparation” and teaches a cosmetic composition comprising the hydrodispersion as rejected above and further that the field of cosmetics includes application to skin and eye region ([0004], [0005]). Thus, one of ordinary skill in the art would have considered forming the same composition for use as a skincare cream. Regarding claim 79, Kruse does not explicitly teach hydrodispersion comprises olus oil and candelilla wax. However, Amela (page 20) teaches O/W emulsion (hydrodispersion) as shown in Example 1-12, where Cegesoft® PS 6 (olus oil) at 3% w/w is used as part of the oil phase. Amela (page 16, line 20-21; emphasis added) also teaches PNG media_image1.png 58 670 media_image1.png Greyscale Therefore, Amela clearly discloses that in addition of natural oils, such as olus oil, natural waxes such as candelilla wax may be included in the same cosmetic preparation, as an example. Therefore, it would have been obvious to a POSITA to combine the teachings of Kruse and Amela to arrive at the claim invention. This indicates that Amela provides clear guidance on the use of olus oil and candelilla wax together in the same hydrodispersion, which would improve moisturizing, stabilizing and texturizing of the formulation. Regarding claim 80, Kruse ([0022] and [0061]) teaches a hydrodispersion containing emollients such as shea butter and humectants such as glycerin. Kruse ([0060]) teaches the use of polyacrylate polymers as thickening agent, which is also supported by Amela (page 14, line 25-28). While Kruse does not explicitly disclose sodium polyacrylate, however, sodium polyacrylate is a known species within the broader class of polyacrylate-based polymers and widely used in personal-care compositions. Therefore, it would have been obvious to a POSITA to select sodium polyacrylate as a suitable polyacrylate polymer based because of its solubility and also more cost effective than other synthetic polyacrylate-based polymer such as cabopoles, to arrive at the claimed invention. Given that sodium polyacrylate is a thickening agent and functioned similarly to other polyacrylate polymer, thus selecting sodium polyacrylate would be an obvious option because of improving water retention more than a polyacrylate polymer. Claims 62, 66, 69, 71 are rejected under 35 U.S.C. 103 as being unpatentable over Kruse et al. (EP 1 889 596) as applied to claims 59-61, 63-65, 67, 68, 70, 72-76 and 79-80 above and further in view of Heidenfelder et al. (US PG-PUB 2003/0124158). Regarding claims 62 and 71, “wherein the hydrodispersion is free of emulsifiers”, the instant specification states “in accordance with the invention, are still regarded as being ‘free of’ emulsifiers and surfactants if the proportion thereof does not exceed 0.1% by weight, based on the total mass of the formulation” (Spec. p. 12). Kruse does not specifically teach “emulsifier free”, however Heidenfelder teaches emulsifier free oil-in-water cosmetic compositions that reduce or avoid the use of emulsifiers to avoid allergic reactions ([0017]). One of ordinary skill in the art following the teaching of Kruse would reasonably consider formulations to reduce or eliminate emulsifiers as suggested by Heidenfelder and arrive at the claimed invention. Regarding claim 69, as with claim 62 and not containing any surfactants, Kruse does not teach surfactants. Almirall, LLC v. Amneal Pharm., 28 F.4th 265, 273 (Fed. Cir. 2022) (“"[A] reference need not state a feature's absence in order to disclose a negative limitation." AC Techs., S.A. v. Amazon.com, Inc. , 912 F.3d 1358, 1367 (Fed. Cir. 2019).”). Regarding claim 66, Kruse teaches the use of waxes but does not specify candelilla wax. However, candelilla wax was well known in the art in cosmetic compositions as taught by Heidenfelder ([0141]). One of ordinary skill in the art would have considered using well-known waxes in the art and arrive at the claimed invention. Conclusion The claims are not in condition for allowance. A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to PIERRE PAUL ELENISTE whose telephone number is (571)270-0589. The examiner can normally be reached on Monday - Friday 8:00 am - 5:00 pm (EST). Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, JAMES H ALSTRUM-ACEVEDO can be reached on (571) 272-5548. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /P.P.E./Examiner, Art Unit 1622 /JAMES H ALSTRUM-ACEVEDO/Supervisory Patent Examiner, Art Unit 1622
Read full office action

Prosecution Timeline

May 19, 2015
Application Filed
Nov 28, 2016
Non-Final Rejection — §103
Mar 31, 2017
Response Filed
Jul 27, 2017
Final Rejection — §103
Sep 27, 2017
Response after Non-Final Action
Nov 30, 2017
Request for Continued Examination
Dec 04, 2017
Response after Non-Final Action
Jan 05, 2018
Non-Final Rejection — §103
May 16, 2018
Response Filed
Aug 11, 2018
Final Rejection — §103
Oct 15, 2018
Response after Non-Final Action
Dec 14, 2018
Notice of Allowance
Mar 13, 2019
Response after Non-Final Action
Mar 27, 2019
Response after Non-Final Action
May 23, 2019
Response after Non-Final Action
Aug 02, 2019
Response after Non-Final Action
Aug 02, 2019
Response after Non-Final Action
Aug 02, 2019
Response after Non-Final Action
Aug 05, 2019
Response after Non-Final Action
Jun 18, 2020
Response after Non-Final Action
Aug 21, 2020
Request for Continued Examination
Aug 26, 2020
Response after Non-Final Action
Sep 24, 2020
Non-Final Rejection — §103
Jan 28, 2021
Response Filed
Feb 19, 2021
Final Rejection — §103
Apr 23, 2021
Response after Non-Final Action
Jun 23, 2021
Notice of Allowance
Sep 21, 2021
Response after Non-Final Action
Sep 28, 2021
Response after Non-Final Action
Nov 10, 2021
Examiner Interview (Telephonic)
Nov 19, 2021
Response after Non-Final Action
Nov 19, 2021
Examiner Interview Summary
Feb 02, 2022
Response after Non-Final Action
Feb 02, 2022
Response after Non-Final Action
Feb 03, 2022
Response after Non-Final Action
Feb 03, 2022
Response after Non-Final Action
Feb 17, 2023
Response after Non-Final Action
Apr 20, 2023
Request for Continued Examination
Apr 26, 2023
Response after Non-Final Action
Oct 06, 2023
Final Rejection — §103
Dec 11, 2023
Response after Non-Final Action
Feb 09, 2024
Notice of Allowance
May 08, 2024
Response after Non-Final Action
May 15, 2024
Response after Non-Final Action
Jun 26, 2024
Response after Non-Final Action
Aug 30, 2024
Response after Non-Final Action
Sep 03, 2024
Response after Non-Final Action
Sep 04, 2024
Response after Non-Final Action
Sep 04, 2024
Response after Non-Final Action
Jun 30, 2025
Response after Non-Final Action
Aug 29, 2025
Request for Continued Examination
Sep 05, 2025
Response after Non-Final Action
Nov 25, 2025
Non-Final Rejection — §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12590099
INHIBITORS OF HISTONE DEACETYLASE USEFUL FOR THE TREATMENT OR PREVENTION OF HIV INFECTION
2y 5m to grant Granted Mar 31, 2026
Patent 12590057
CRYSTALLINE COMPLEXES
2y 5m to grant Granted Mar 31, 2026
Patent 12583873
AMINO ACID MINERAL COMPLEX HAVING IMMUNOPOTENTIATING ACTIVITY AND COMPOSITION FOR FOODS, PHARMACEUTICALS, OR FEEDS COMPRISING SAME
2y 5m to grant Granted Mar 24, 2026
Patent 12545672
ANTIBIOTIC COMPOUNDS, METHODS OF MANUFACTURING THE SAME, PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME AND USES THEREOF
2y 5m to grant Granted Feb 10, 2026
Patent 12545639
3-SUBSTITUTED PHENYLAMIDINE COMPOUNDS, PREPARATION AND USE THEREOF
2y 5m to grant Granted Feb 10, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

8-9
Expected OA Rounds
39%
Grant Probability
71%
With Interview (+31.6%)
3y 6m
Median Time to Grant
High
PTA Risk
Based on 69 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month